Europe Obsessive-Compulsive Disorder (OCD) Drugs Market, By Severity (Mild to Moderate, Moderate to Severe), By Sub-Type (Contamination Obsessions with Washing/Cleaning Compulsion, Harm Obsessions With Checking Compulsions, Obsessions Without Visible Compulsions, Symmetry Obsessions with ordering, arranging and counting compulsions, hoarding, others), By Drugs (Antidepressants, Antipsychotics, NMDA Blocker, Others), By Route of Administration (Oral, Parenteral), By Population type (Pediatrics, Adults), By End User (Hospitals, specialty Clinics, Home healthcare, others), By Distribution Channel (Hospital pharmacy, Retail Pharmacy, Online Pharmacy, Others) By Country (France, U.K., Italy, Germany, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe).
Market Analysis and Insights: Europe Obsessive-Compulsive Disorder (OCD) Drugs Market
Europe Obsessive-Compulsive Disorder (OCD) Drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.2% in the forecast period of 2021 to 2028 and is expected to reach USD 274.47 million by 2028. Increasing generic approvals and awareness among people regarding the disorder and treatment products available are the major drivers which propelled the demand of the market in the forecast period.
Obsessive-compulsive disorder (OCD) refers to an anxiety disorder that is characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market. However, patent expiry of the patented drugs and introduction of generic version of branded drugs are factors expected to restraint the market growth in the forecast period.
The OCD drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Obsessive-Compulsive Disorder (OCD) Drugs Market Scope and Market Size
Obsessive-Compulsive Disorder (OCD) Drugs Market is segmented on the basis of severity, subtypes, drugs, route of administration, population, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the Europe obsessive obsessive-compulsive disorder (OCD) drugs market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe are predicted to dominate the market.
- On the basis of subtype, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging and counting compulsions, hoarding and others. In 2021, contamination obsessions with washing/cleaning compulsion is are dominating the Europe obsessive obsessive-compulsive disorder drug market due to developments in the treatment, therapies, and introduction of novel treatments are predicted to dominate the market.
- On the basis of drugs, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into antidepressants, antipsychotics, NMDA blocker and others. Antidepressants is further segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAS) and others. SSRIs is further segmented into fluvoxamine, fluoxetine, paroxetine, sertraline and others. SNRIs is further segmented into duloxetine, venlafaxine and others. TCAS is further segmented into clomipramine, amitriptyline, imipramine and others. Antipsychotics is further segmented into risperidone, haloperidol, quetiapine, olanzapine, aripiprazole and others. NMDA blocker is further segmented into ketamine, memantine and others. In 2021, the antidepressants segment is dominating the Europe obsessive obsessive-compulsive disorder drug market due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the robust pipelines for the development of newer treatment are predicted to dominate the market.
- On the basis of route of administration, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablet, capsules and solution. In 2021, the oral segment is dominating the Europe obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment and advancements in therapies are predicted to dominate the market.
- On the basis of population, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the Europe obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market.
- On the basis of end user, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Europe obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
- On the basis of distribution channel, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Europe obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.
- In Europe, U.K. is the dominant region due to rising cases of genetic inherited disorders and rising adoption of gene therapy.
Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis
The OCD drugs market is analyzed and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user and distribution channel.
The countries covered in the OCD drugs market report are France, U.K., Italy, Germany, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.
Oral segment in Europe region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of the developments in the treatment, therapies and novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs and improving healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic initiatives by market players and rise in demand of OCD drugs are boosting the Market Growth of OCD drugs products.
Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and OCD Market Share Analysis
OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.
The major companies which are dealing in the Obsessive-Compulsive Disorder (OCD) drugs are H. LUNDBECK A/S, Apotex Inc., Teva Pharmaceutical industries Ltd. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Lannett, GlaxoSmithKline plc., Pfizer Inc., Mallinckrodt, Sebela Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., , Wockhardt, Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Abbott, Eli Lilly and Company, Viatria Inc., among others.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the OCD drugs market.
For instance,
- In January 2021, Lundbeck enters a new partnership with the Department of Neurosurgery (Afdeling for Hjerne- og Nervekirurgi) at Rigshospitalet in Copenhagen, which will provide new insights into how molecules enter the brain. The partnership gives researchers an opportunity to study fluids surrounding the brain to learn which compounds enter the brain and how they are distributed. The project is basic research, with a view to making the results widely available.
- In April 2021, Apotex inc. announced the initiation of voluntary type 1 recall of APO-AMITRIPTYLINE 10mg. The recall is initiated due to the one lot (PY1831) in which the acceptable intake limit of NDMA, as established by Health Canada, has been exceeded. This has somehow caused financial loss to the company.
- In March 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the OCD drugs market which also provides the benefit for organization to improve their offering for OCD drugs products. .
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR OCD DRUGS
6.2 EUROPE REGULATORY FRAMEWORK FOR OCD DRUGS
6.3 AUSTRALIA REGULATORY GUIDANCE ON OCD DRUGS
7 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REIMBURSEMENT SCENARIO
8 COST ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.1.2 INCREASING CASES OF OBSESSIVE-COMPULSIVE DISORDER (OCD) WORLDWIDE
9.1.3 INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS
9.1.4 CHANGES IN LIFESTYLE AND ENVIRONMENTAL STRESS AMONG PEOPLE
9.1.5 INCREASING GENERIC APPROVALS
9.2 RESTRAINTS
9.2.1 RECALL OF DRUGS
9.2.2 ADVERSE EFFECTS OF DRUGS
9.2.3 STRINGENT GOVERNMENT REGULATIONS FOR OCD DRUGS DEVELOPMENT
9.2.4 UNAWARENESS AMONG PEOPLE OF EXISTENCE OF OCD
9.3 OPPORTUNITIES
9.3.1 TECHNOLOGICAL ADVANCEMENT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.3.2 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
9.3.3 RISE IN QUALITY CONCERNS
9.4 CHALLENGES
9.4.1 USE OF ALTERNATIVE THERAPIES
9.4.2 LIMITATIONS OF CURRENT OCD TREATMENT
10 IMPACT OF COVID-19 ON EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 MARKET BY DRUGS
11.1 TOTAL ADDRESSABLE MARKET
11.2 PATIENT POPULATION (2019-2028)
12 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY
12.1 OVERVIEW
12.2 MODERATE TO SEVERE
12.3 MILD TO MODERATE
13 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE
13.1 OVERVIEW
13.2 CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION
13.3 HARM OBSESSIONS WITH CHECKING COMPULSIONS
13.4 OBSESSIONS WITHOUT VISIBLE COMPULSIONS
13.5 SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS
13.6 HOARDING
13.7 OTHERS
14 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS
14.1 OVERVIEW
14.2 ANTIDEPRESSANTS
14.2.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
14.2.1.1 FLUVOXAMINE
14.2.1.2 FLUOXETINE
14.2.1.3 PAROXETINE
14.2.1.4 SERTRALINE
14.2.1.5 OTHERS
14.2.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
14.2.2.1 DULOXETINE
14.2.2.2 VENLAFAXINE
14.2.2.3 OTHERS
14.2.3 TRICYCLIC ANTIDEPRESSANTS
14.2.3.1 CLOMIPRAMINE
14.2.3.2 AMITRIPTYLINE
14.2.3.3 IMIPRAMINE
14.2.3.4 OTHERS
14.3 ANTIPSYCHOTICS
14.3.1 RISPERIDONE
14.3.2 OLANZAPINE
14.3.3 ARIPIPRAZOLE
14.3.4 QUETIAPINE
14.3.5 HALOPERIDOL
14.3.6 OTHERS
14.4 NMDA BLOCKERS
14.4.1 MEMANTINE
14.4.2 KETAMINE
14.4.3 OTHERS
14.5 OTHERS
15 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULE
15.2.3 SOLUTION
15.3 PARENTERAL
16 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION
16.1 OVERVIEW
16.2 ADULTS
16.3 PEDIATRICS
17 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION
19.1 EUROPE
19.1.1 U.K.
19.1.2 FRANCE
19.1.3 GERMANY
19.1.4 ITALY
19.1.5 SPAIN
19.1.6 NETHERLANDS
19.1.7 RUSSIA
19.1.8 SWITZERLAND
19.1.9 TURKEY
19.1.10 AUSTRIA
19.1.11 NORWAY
19.1.12 HUNGARY
19.1.13 LITHUANIA
19.1.14 POLAND
19.1.15 IRELAND
19.1.16 REST OF EUROPE
20 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: EUROPE
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 H. LUNDBECK A/S
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 ELI LILLY AND COMPANY
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 APOTEX INC.
22.5.1 COMPANY SNAPSHOT
22.5.2 COMPANY SHARE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 VIATRIS INC.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 LANNETT
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 GLAXOSMITHKLINE PLC
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 ALVOGEN
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 PFIZER INC.
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 AMNEAL PHARMACEUTICALS LLC
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 DR.REDDY’S LABORATORIES LTD.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 ABBOTT
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 LUPIN PHARMACEUTICALS, INC.
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
22.16 MALLINCKRODT
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 PRODUCT PORTFOLIO
22.16.4 RECENT DEVELOPMENTS
22.17 PAR PHARMACEUTICAL
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENTS
22.18 SEBELA PHARMACEUTICALS
22.18.1 COMPANY SNAPSHOT
22.18.2 PRODUCT PORTFOLIO
22.18.3 RECENT DEVELOPMENT
22.19 ZYDUS PHARMACEUTICALS USA INC. (A SUBSIDIARY OF ZYDUS CADILA)
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 PRODUCT PORTFOLIO
22.19.4 RECENT DEVELOPMENTS
22.2 WOCKHARDT
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 PRODUCT PORTFOLIO
22.20.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 BELOW MENTIONED ARE THE COST OF OCD DRUGS, AVAILABLE IN DIFFERENT DOSAGE FORMS SUCH AS A TABLET, CAPSULE, PARENTAL, AND STRENGTHS USED EUROPELY TO TREAT OBSESSIVE-COMPULSIVE DISORDER.
TABLE 2 DRUGS UNDER INVESTIGATIONS FOR OCD
TABLE 3 R&D COST BY KEY MARKET PLAYERS (USD MILLIONS) (2020)
TABLE 4 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 5 EUROPE MODERATE TO SEVERE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE MILD TO MODERATE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE 2019-2028 (USD MILLION)
TABLE 8 EUROPE CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE HARM OBSESSIONS WITH CHECKING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE OBSESSIONS WITHOUT VISIBLE COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE HOARDING IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 15 EUROPE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 18 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 19 EUROPE TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 20 EUROPE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 22 EUROPE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 24 EUROPE OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE PARENTERAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE ADULTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 31 EUROPE PEDIATRICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 EUROPE HOSPITALS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE SPECIALTY CLINICS IN OBSESSIVE-COMPULSIVE (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE HOME HEALTHCARE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 38 EUROPE HOSPITAL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE RETAIL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE ONLINE PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 44 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 45 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 46 EUROPE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 47 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 48 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 49 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 50 EUROPE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 51 EUROPE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 52 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 59 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 60 U.K. ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 61 U.K. SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 62 U.K. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 63 U.K. TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 64 U.K. ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 65 U.K. NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 66 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 U.K. ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 69 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 U.K. OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 72 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 73 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 74 FRANCE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 75 FRANCE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 76 FRANCE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 77 FRANCE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 78 FRANCE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 79 FRANCE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 80 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 FRANCE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 83 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 FRANCE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 86 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 87 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 88 GERMANY ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 89 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 90 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 91 GERMANY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 92 GERMANY ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 93 GERMANY NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 94 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 GERMANY ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 97 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 GERMANY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 100 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 101 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 102 ITALY ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 103 ITALY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 104 ITALY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 105 ITALY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 106 ITALY ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 107 ITALY NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 108 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 ITALY ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 111 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 ITALY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 114 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 115 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 116 SPAIN ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 117 SPAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 118 SPAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 119 SPAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 120 SPAIN ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 121 SPAIN NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 122 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 SPAIN ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 125 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 SPAIN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 128 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 129 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 130 NETHERLANDS ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 131 NETHERLANDS SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 132 NETHERLANDS SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 133 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 134 NETHERLANDS ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 135 NETHERLANDS NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 136 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 NETHERLANDS ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 140 NETHERLANDS OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 142 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 143 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 144 RUSSIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 145 RUSSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 146 RUSSIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 147 RUSSIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 148 RUSSIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 149 RUSSIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 150 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 RUSSIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 153 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 154 RUSSIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 155 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 156 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 157 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 158 SWITZERLAND ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 159 SWITZERLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 160 SWITZERLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 161 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 162 SWITZERLAND ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 163 SWITZERLAND NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 164 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 SWITZERLAND ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 167 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 168 SWITZERLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 170 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 171 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 172 TURKEY ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 173 TURKEY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 174 TURKEY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 175 TURKEY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 176 TURKEY ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 177 TURKEY NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 178 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 179 TURKEY ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 181 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 TURKEY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 183 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 184 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 185 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 186 AUSTRIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 187 AUSTRIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 188 AUSTRIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 189 AUSTRIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 190 AUSTRIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 191 AUSTRIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 192 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 193 AUSTRIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 194 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 195 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 196 AUSTRIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 197 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 198 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 199 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 200 NORWAY ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 201 NORWAY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 202 NORWAY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 203 NORWAY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 204 NORWAY ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 205 NORWAY NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 206 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 NORWAY ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 209 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 210 NORWAY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 211 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 212 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 213 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 214 HUNGARY ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 215 HUNGARY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 216 HUNGARY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 217 HUNGARY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 218 HUNGARY ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 219 HUNGARY NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 220 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 221 HUNGARY ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 222 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 223 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 224 HUNGARY OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 225 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 226 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 227 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 228 LITHUANIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 229 LITHUANIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 230 LITHUANIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 231 LITHUANIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 232 LITHUANIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 233 LITHUANIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 234 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 235 LITHUANIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 236 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 237 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 238 LITHUANIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 239 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 240 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 241 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 242 POLAND ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 243 POLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 244 POLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 245 POLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 246 POLAND ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 247 POLAND NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 248 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 249 POLAND ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 250 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 251 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 252 POLAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 253 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 254 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 255 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 256 IRELAND ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 257 IRELAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 258 IRELAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 259 IRELAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 260 IRELAND ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 261 IRELAND NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 262 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 263 IRELAND ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 265 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 266 IRELAND OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 267 REST OF EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 2 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DATA TRIANGULATION
FIGURE 3 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DROC ANALYSIS
FIGURE 4 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DBMR MARKET POSITION GRID
FIGURE 8 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 11 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER AND INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS ARE EXPECTED TO DRIVE THE EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 SEVERITY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUG MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES ABD CHALLENGES OF EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
FIGURE 14 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020
FIGURE 15 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020-2028 (USD MILLION)
FIGURE 16 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, CAGR (2021-2028)
FIGURE 17 EUROPE OBSESSIVE-COMPULSIVE DIOSRDER (OCD) DRUG MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020
FIGURE 19 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020-2028 (USD MILLION)
FIGURE 20 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, CAGR (2020-2028)
FIGURE 21 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, LIFELINE CURVE
FIGURE 22 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020
FIGURE 23 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020-2028 (USD MILLION)
FIGURE 24 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, CAGR (2020-2028)
FIGURE 25 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 26 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 29 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020
FIGURE 31 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020-2028 (USD MILLION)
FIGURE 32 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, CAGR (2021-2028)
FIGURE 33 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY, LIFELINE CURVE
FIGURE 34 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020
FIGURE 35 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 36 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 40 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: SNAPSHOT (2020)
FIGURE 43 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020)
FIGURE 44 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020 & 2028)
FIGURE 46 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY (2021 & 2028)
FIGURE 47 EUROPE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
